Therapeutic Strategy for Pathological Cardiac Hypertrophy
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pharmacology".
Deadline for manuscript submissions: closed (22 August 2023) | Viewed by 2810
Special Issue Editor
Interests: preclinical models; in vivo models of cardiac hypertrophy and cardiotoxicity; cardiovascular disease; obesity; mitochondrial damage; cardio-oncology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Pathological cardiac hypertrophy is a key risk factor for heart failure. Increased interstitial fibrosis, cardiac dysfunction and cell death are essential features of pathological cardiac hypertrophy. The numerous mediators that have been found as involved in the pathogenesis of maladaptive heart growth can affect gene transcription, calcium handling, protein synthesis, metabolism, mitochondrial function, autophagy, oxidative stress and inflammation. Many of the molecular mechanisms and dysregulated signaling pathways implicated in promoting malignant remodeling have been unrevealed. Focusing on these key regulation points seems to be an important target for defining innovative strategies for the management of pathological hypertrophy.
This special issue aims to take stock of advances in the development and validation of therapeutic strategies against pathological cardiac hypertrophy, both in preclinical and clinical studies. Research papers and up-to-date review articles are all welcome on various topics including, but not limited to, either conventional drug strategies or novel therapeutic approaches (e.g., RNA-based therapies, dietary supplementation, drug delivery systems) targeting molecular pathways involved in the transition to hypertrophic maladaptive remodeling of the heart.
Dr. Claudia Kusmic
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- myocardial hypertrophy
- cardiac remodeling
- heart failure
- drug therapy
- molecular therapeutic targets
- myocardial gene therapy
